Goodbye boutique CRO, hello large study BIG PLAYER! For a long time, you’ve known us as THE high quality outfit that can stabilize difficult assays in the initial stages of clinical investigation. But we’ve been investing in additional technical personnel and laboratory capacity for translational medicine at our Flagship Delaware Technology Park facility. And now […]
Translational Medicine Now Bigger and Better at QPS Read More »
The 2017 Transdermal & Intradermal Drug Delivery Systems conference covering Advanced Design, Development & Delivery of Skin-Mediated Therapies and Vaccines is coming up on September 28-29 at the venerable Racquet Club of Philadelphia. Don’t miss Paul Lehman, VP and Head of Dermal & Transdermal Research Services at QPS, presenting “Evolution of the In Vitro Permeation
QPS’ Paul Lehman to Speak at Transdermal & Intradermal Drug Delivery Conference Read More »
Two companies have just selected QPS Netherlands to conduct their First-in-Human studies. Acticor Biotech, a Paris-based biotechnology company focused on the treatment of acute ischemic stroke, selected the QPS facility in Groningen, The Netherlands, to manage a Phase I clinical study. The goal of the study is to assess safety and tolerance as well as
QPS Tapped for Two New FIH Studies Read More »
An investigation into the efficacy and safety of Estetrol (E4) for potential use in the treatment of advanced prostate cancer demonstrated decreased testosterone levels along with acceptable safety parameters. These results suggest that E4 may be suitable for standalone or combination treatment with androgen deprivation therapy (ADT). QPS Netherlands performed the Phase II randomized, double-blind,
QPS Study Shows Estetrol Promising for Prostate Cancer Treatment Read More »
Each year, Life Science Leader honors CROs that are the top performers in Compatibility, Capabilities, Expertise, Quality, and Reliability. To determine the winners, the magazine teams up with Industry Standard Research (ISR). ISR looks at 27 different performance metrics, as rated by decision-making executives at biopharmaceutical companies. “Real customers provide experiential feedback on their involvement
Another CRO Leadership Award! For Compatibility, Expertise, Quality and Reliability Read More »
Patient recruitment is one of the most critical foundations of any clinical trial. Effective patient recruitment sets the trial down a path toward success if done well, or can create a road full of potholes if managed incorrectly. On April 11th, Barbara Derler, PhD, heading the EU patient recruitment team from the QPS site in
QPS has been assisting an international Sponsor to perform a global, late-phase study to investigate the safety, efficacy, and pharmacokinetic behavior of an investigational drug in subjects with advanced prostate carcinoma. The original enrollment goal was 133 patients to be enrolled in approximately 18 months. The QPS Global Clinical Operations team enrolled 137 patients at
QPS has been assisting an international Sponsor to perform a global, late-phase study to investigate the safety, efficacy, and pharmacokinetic behavior of a newly formulated investigational drug in subjects with advanced prostate carcinoma. The original enrollment goal was 133 patients to be enrolled in approximately 18 months. The QPS Global Clinical Operations team enrolled 137
The European Medicines Agency (EMA) has released a draft guideline revision on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias for a six-month public consultation. The EMA considers dementia a key public health priority and sees early stage intervention and prevention of symptomatic disease as particularly worthy goals. This
Consultation open on revised EMA Guideline on Medicines to treat Alzheimer’s Disease Read More »
The role of Mg in human nutrition has recently received renewed interest. Mg dietary intake has been reported to have decreased during the last 100 years in Western countries. For example, in the US it is often below the recommended dietary allowances. Decreased Mg intake and/or low serum Mg have been associated with a number
On February 23, Professor Zuzana Diamant, MD PhD, Director of Respiratory & Allergy Research at QPS, will talk about Biomarkers in Respiratory Drug Development and personalized medicine at the Informa-sponsored Early Clinical Development conference, Amba Hotel Marble Arch, London. In her lecture, Professor Diamant will cover the following topics: Definition of a valuable biomarker Which
Making the right decision about where to conduct Phase I of a clinical trial is crucial. As long as basic EU regulatory requirements are fulfilled, the investigational site may be located anywhere in the world. This paper will walk you through the three key essential considerations for clinical trials intended to support registration in the
Read the QPS Whitepaper on Phase I Site Selection to support EU Registration Read More »
The focus of this seminar is on increasing the success of Biotech. Participation is free of charge. When and where: September 15th, 2015 16:00 – 17:30 Hotel Vier Jahreszeiten Starnberg Münchner Straße 17 82319 Starnberg, Germany Agenda: 16:00 – 16:15 Opening, Izaak den Daas, PhD, Principal Scientist QPS 16:15 – 16:30 Problems and Challenges for
Okay, we’ll admit it: a company telling you about their new brochure seems about as interesting as looking through your Great Uncle’s vacation pictures – for the tenth time. But we can’t help it. We’re really excited about this one! That’s because we’re proud to provide specialized, collaborative Clinical Development services that help us build
QPS was able to deliver on this extremely challenging early phase clinical trial because we have access to the expertise of a university anaesthesiology department in the Netherlands, and its associated facilities. See details below
Ever wish that really big hill you always cycle up would seem a little less hilly? Want to swing impressive poundage at your next kettlebell class?According to Doug Kalman PhD, RD, Director of Nutrition & Endocrinology at QPS MRA (Miami Research Associates) and other contributors to the International Society of Sports Nutrition’s position paper on
Cannabinoid bioscience has come a long way. New York-based Axim Biotech is at the forefront, developing – among many other, related products – a multi-layered, slow-release cannabinoid chewing gum. Not for the candy stand, MedChewRx® is seeking FDA and EMA approval for the treatment of pain and spasticity associated with multiple sclerosis. Characteristically, QPS is
QPS Aids Development of Cannabinoid Chewing Gum, for MS Patients Read More »
Finding something tasty to drink at the mini-mart has gotten really complicated lately. Knowing the usual soft drinks are unhealthy, you may be tempted by the “sport” drink section. But even if you’ve grabbed the colorless option to avoid massive quantities of Blue #1 or Yellow #5, a quick label-read may have you flipping that
The sheer abundance of diet drugs available suggests two things: 1) there is a huge market for them and 2) none of them work significantly better than the rest (if at all.) Imagine the excitement, then, at finding that an agent already prescribed for diabetes really can help patients lose significant amounts of weight. And
In July 2015, regulatory expert Patricia Baede joined QPS’ clinical development teams. With 20 years of experience in clinical trial conduct and all regulatory aspects of drug development, Baede adds EU regulatory support to the growing portfolio of clinical activities QPS provides. In the past, she has worked on drug development teams as Phase I
Regulatory Expertise Now Part of QPS Clinical Development Offerings Read More »
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
